LoVo Cell Line
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Insights on Lovo cells
| Description | The LOVO cell line, derived from a grade IV Dukes' type C colon adenocarcinoma, is characterized by mutations in the adenomatous polyposis coli (APC) gene, Kirsten rat sarcoma viral oncogene homolog (KRAS), and tumor protein p53 (TP53). These genetic features are instrumental in studying the molecular basis of colorectal cancer progression, metastasis, and drug resistance mechanisms. LoVo cells serve as a critical model for screening anti-cancer compounds and by understanding how cancer cells like LoVo develop resistance, researchers can design more effective therapies. LoVo cells are also employed in molecular biology studies to explore signaling pathways that regulate cancer cell growth, survival, and metastasis. In the context of human colon cancer and colorectal cancer cell lines, LoVo cells offer insights into the mechanisms of tumor growth and the process of metastasis, particularly node metastasis, and the tumor microenvironment driving cancer progression. The use of LoVo colon cancer cells, especially in lovo xenograft models, allows researchers to study cancer cell dynamics and metastatic potential. Deep sequencing and gene expression analysis in LoVo cells have shed light into the specific genes and their roles in colorectal cancer cells. This research has has highlighted the importance of integrins, such as integrin β1, in cancer cell migration and invasion, and the regulation of key molecules like MMP2 in signaling pathways contributing to the understanding of cancer cell lines' invasive properties. LoVo cells, as a model system in colorectal cancer cell lines, play a pivotal role in advancing our understanding of the molecular aspects of cancer, from gene and protein expression to the intricacies of tumor growth and metastasis. |
|---|---|
| Organism | Human |
| Tissue | Colon, grade IV, Dukes' type C |
| Disease | Adenocarcinoma |
| Metastatic site | Left supraclavicular lymph node |
| Synonyms | LOVO |
Aspects
| Age | 56 years |
|---|---|
| Gender | Male |
| Morphology | Epithelial-like |
| Growth properties | Adherent |
Documentation about LoVo cells
| Citation | LoVo (Cytion catalog number 300266) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0399 |
Genomics
| Antigen expression | HLA A11, B15, B17, Cw1, Cw3, blood type B |
|---|---|
| Isoenzymes | G6PD, B, PGM1, 2, PGM3, 1-2, 6PGD, A, ES-D, 1 |
| Oncogenes | Myc +, myb + , ras +, fos +, p53 +, sis -, abl -, ros -, src - |
| Tumorigenic | Yes, in nude mice |
| Reverse transcriptase | Negative |
| Products | Carcinoembryonic antigen (CEA) 908 ng/106 cells/10 days |
| Mutational profile | LOVO cells carry a mutation in codon 13 of Kras gene: GGC(Wt Gly) >GAC(Asp) |
Handling the LoVo cell line
| Culture Medium | Ham's F12K Medium, w: 2.0 mM L-Glutamine, w: 2.0 mM Sodium pyruvate, w: 2.5 g/L NaHCO3 (Cytion article number 820608a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1 x 104 cells/cm2 |
| Fluid renewal | 2 to 3 times per week |
| Post-Thaw Recovery | After thawing, plate the cells at 5 x 104 cells/cm2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality control
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300266-140825 | Certificate of Analysis | 22. Oct. 2025 | 300266 |
-
Related products
Related products
SW480 CellsOrganism Human Tissue Colon Disease Adenocarcinoma, Grade IV, Dukes' type B. CAD$545.10*